Approval · Notice of Compliance 35465 · 2025
NB-VALACYCLOVIR: Notice of Compliance 35465
Issued June 3, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35465
- Date
- June 3, 2025
- Company
- NB Pharma Inc.Québec, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement between two manufacturers
- Canadian reference product
- VALTREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NB-VALACYCLOVIR | 02558130 | Marketed |
| NB-VALACYCLOVIR | 02558149 | Approved |
Medicinal ingredients
- VALACYCLOVIR 500 MG per TAB
- VALACYCLOVIR 1,000 MG per TAB